| HOME >> MEDICINE >> TECHNOLOGY |
21,9773,25924,1667,184Operating ExpensesCost of manufacturing services
6522,2771,4434,658Research and development
14,07614,70328,54630,638General and administrative
5,2166,07711,57112,967Restructuring charges
0003,467Amortization of acquired technology & other intangibles
173186349622 Total operating expenses
20,11723,24341,90952,352Interest and Other Income (Expense)Interest income
25334082Interest expense
(2,489)(3,182)(5,520)(7,876)Gain (Loss) from valuation of derivative liabilities
(16,770)181(19,145)620Loss on extinguishment of debt
(4,668)0(6,338)(10,514)Other
(57)443050 Total interest and other expense, net
(23,959)(2,924)(30,933)(17,638)Net loss
(22,099)(22,908)(48,676)(62,806)Deemed dividend related to beneficial conversion feature
of convertible preferred stock
00(2,824)(2,260)Net loss allocable to common stockholders
$(22,099)$(22,908)$(51,500)$(65,066)Net loss per share allocable to common stockholders:Basic
$
(0.12)$
(0.16)$
(0.29)$
(0.49)Diluted
$
(0.12)$
(0.16)$
(0.29)$
(0.49)Shares used in calculating net loss per share allocable
to common stockholders:Basic
190,272142,693177,243132,232Diluted
190,272142,693177,243132,232Arena Pharmaceuticals, Inc.Condensed Consolidated Balance Sheet Data(In thousands)June 30, 2012December 31, 2011(unaudited)1Assets Cash and cash equivalents
$ 143,811$ 57,632 Accounts receivable
20,578607 Other current assets
2,8632,021 Land, property & equipment, net
77,64282,066 Acquired technology & other non-current assets
14,10914,803Total assets
$ 259,003$ 157,129Liabilities and Stockholders' Equity Accounts payable and accrued liabilities
$ 7,
'/>"/>
| SOURCE Arena Pharmaceuticals, Inc. Copyright©2012 PR Newswire. All rights reserved |